l*****1
发帖数: 8 | 1 http://www.ncbi.nlm.nih.gov/pubmed?term=20551945
Nature Reviews Clinical Oncology 7, 401-414 (July 2010) | doi:10.1038/
nrclinonc.2010.64
Targeted therapy in non-small-cell lung cancer—is it becoming a reality?
Filip Janku, David J. Stewart & Razelle Kurzrock
Abstract
Treatment outcomes in advanced or metastatic non-small-cell lung cancer (
NSCLC) remain unsatisfactory, with low long-term survival rates. Palliative
chemotherapy offers a median survival not exceeding 1 year. To date, various
combinations of cytotoxic drugs have not improved treatment results beyond
what has been observed with platinum doublets. By contrast, molecular
targeted drugs may block important pathways that drive cancer progression
and achieve long-term disease control. Conflicting results have demonstrated
marginal benefit with EGFR inhibitors, anti-EGFR monoclonal antibodies and
antiangiogenic strategies in unselected populations of patients with
advanced NSCLC. However, patients with an EGFR mutation are likely to
respond to agents that target this gene. Novel targeted therapies that
interfere with insulin-like growth factor 1 receptor, or the EML4-ALK fusion
protein have shown promising activity. Aberrations in other key signaling
pathways and molecules, such as RAS/RAF/MEK, PI3K/AKT/mTOR, or MET kinase,
have been identified as crucial targets, especially in resistant patients.
Novel drugs aimed at these abnormalities are already in the clinic. This
Review outlines the current state-of-the-art research for targeted therapy
in NSCLC.
Please send to : l*******[email protected].
Thank you very much. | c*****k
发帖数: 160 | |
|
